For research use only. Not for therapeutic Use.
Tepotinib（Cat No.:I000414）is a potent, selective MET tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. By targeting the MET signaling pathway, Tepotinib inhibits tumor growth and metastasis. Its precision-targeted mechanism allows for effective intervention in patients with MET-driven cancers, offering a personalized approach to therapy. Tepotinib’s favorable pharmacokinetics and manageable safety profile make it a valuable option in advanced NSCLC treatment, addressing an unmet medical need in oncology.
| Catalog Number | I000414 |
| CAS Number | 1100598-32-0 |
| Synonyms | 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile |
| Molecular Formula | C29H28N6O2 |
| Purity | 98% |
| Target | MET |
| Target Protein | |
| Solubility | DMSO: ≤ 27 mg/mL |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | EBC-1 lung cancer cells, tepotinib potently inhibited MET phosphorylation (IC50 = 1.1 nmol/L) |
| IUPAC Name | 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile |
| InChI | InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3 |
| InChIKey | AHYMHWXQRWRBKT-UHFFFAOYSA-N |
| SMILES | CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N |
